Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Pattern Bioscience Scoops Up $28.7M Series C

2023-04-27
AUSTIN, TX, Pattern Bioscience, an innovator in rapid diagnosis and antibiotic susceptibility testing for bacterial infections, today announced the completion of a $28.7 million Series C financing.
The latest funding round was led by Illumina Ventures and Omnimed Capital and includes participation from the Antimicrobial Resistance Action Fund and Daleshaw Ltd. This new round brings the company's total funding raised to date to $68 million.

Pattern Bioscience aims to save lives by transforming how bacterial infections are diagnosed and to improve global health by reducing the burden of antibiotic resistance. Its single-cell microbiology technology is the first and only culture-free, rapid phenotypic testing platform to deliver clinically actionable results in a timeframe that will enable healthcare teams to get appropriate, life-saving treatments to patients fast enough to make a real difference in outcomes. The company's first tests will be for critically ill patients with pneumonia and bacteremia, identifying both the causal pathogen and its antibiotic susceptibility profile in hours, compared with the days required for traditional culture testing. Pattern Bioscience is a privately held company based in Austin, Texas, led by veterans of the diagnostic industry with deep experience bringing new diagnostic technology to market.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors